Journal profile · Pharmacology & Pharmacy
PHARMACOTHERAPY
ISSN 0277-0008 · eISSN 1875-9114 · Wiley-Blackwell · UNITED STATES · Monthly · Founded 1981
PHARMACOTHERAPY: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.06; hybrid open access; APC about USD 4,030; median 86 days to acceptance (84 articles, last 24 months); community-reported acceptance: easy; 129 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
PHARMACOTHERAPY is published by Wiley-Blackwell and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Antibiotics Pharmacokinetics and Efficacy, Pharmaceutical Practices and Patient Outcomes and Pharmaceutical studies and practices, together about 27.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editorial board by country: none in mainland China; most named Australia 2, Germany 1 (3 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Antibiotics Pharmacokinetics and EfficacyMedicine10.4%
- Pharmaceutical Practices and Patient OutcomesMedicine9.3%
- Pharmaceutical studies and practicesMedicine7.8%
- Atrial Fibrillation Management and OutcomesMedicine5.8%
- Antimicrobial Resistance in StaphylococcusMedicine4.5%
- Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology4.4%
- Venous Thromboembolism Diagnosis and ManagementMedicine4.3%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbasePublisher website
Other: EBSCO, ProQuest, OCLC
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.06LetPub ·
- Impact factor (publisher)
- 4Publisher website ·
- Impact factor (publisher) 2025
- 4Publisher website ·
- CiteScore 2026-06
- 7.2LetPub ·
- CiteScore (publisher)
- 7.2Publisher website ·
- CiteScore (publisher) 2025
- 7.2Publisher website ·
- SJR 2026-06
- 1.19LetPub ·
- SNIP 2026-06
- 1.52LetPub ·
- h-index
- 99LetPub ·
- h-index
- 152OpenAlex ·
- i10-index
- 4,230OpenAlex ·
- 2-year mean citedness
- 2.59OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 27.68%LetPub ·
Volume
- Articles per year
- 83LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 102Publisher website ·
- Downloads per year (publisher) 2025
- 737,289Publisher website ·
Articles by year OpenAlex count · 7,444 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 106 | 51 | 42 |
| 2025 | 129 | 81 | 328 |
| 2024 | 99 | 64 | 496 |
| 2023 | 161 | 105 | 1,800 |
| 2022 | 112 | 46 | 1,563 |
| 2021 | 121 | 34 | 1,545 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
86 daysMedian, submission to acceptance · P25–P75 55 days – 138 days
- Acceptance to online
- median 41 days (84 articles)
- Submission to online
- median 128 days
- Sample
- 84 articles with submission and acceptance dates (243 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
- Acceptance rate (publisher)
- 13%Publisher website ·
- Acceptance rate (publisher) 2025
- 13%Publisher website ·
- Submission to first decision
- 1 daysPublisher website ·
- Submission to first decision 2025
- 1 daysPublisher website ·
- Submission to acceptance 2025
- 85 daysPublisher website ·
- Acceptance to publication 2025
- 39 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,030 / EUR 3,350 / GBP 2,720 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Manuscript length
- ≤ 3,500 words
- Graphical abstract
- Optional
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Open access
- Authorship
Originality: submission implies content has not been published or submitted elsewhere except as a brief abstract in proceedings. Model summary
Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potent…
Source ↗Publisher website ·- Open access Your Open Access fees might be covered
PHARMACOTHERAPY AUTHOR GUIDELINES Sections Submission Aims and Scope Manuscript Categories and Requirements Preparing the Submission Editorial Policies and Ethical Considerations Author Licensing Publication Process After Acceptance Post Publication Editorial Office Contact Details 1. SUBMISSIONAuthors should kindly note that submission implies that the content has not been published or submitted …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1981
- ISSN
- 0277-0008
- Electronic ISSN
- 1875-9114
- Society / sponsor
- American College of Clinical Pharmacy
- Latest issue on the website
- Volume 46, Issue 10 (October 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about PHARMACOTHERAPY
What CAS zone is PHARMACOTHERAPY in?
In the 2025 upgraded edition of the CAS Journal Ranking, PHARMACOTHERAPY is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of PHARMACOTHERAPY?
The latest impact factor listed by LetPub is 4.06; CiteScore 7.2, h-index 152.
How long does peer review take at PHARMACOTHERAPY?
Based on the dates recorded on 84 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 86 days (interquartile range 55–138 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy”; the journal's website gives an acceptance rate of 13% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of PHARMACOTHERAPY?
According to the journal's author guidelines: Manuscript length: ≤ 3,500 words; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of PHARMACOTHERAPY based?
Of the 3 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Australia (2) and Germany (1). Counted from the institutions listed on the board page; for reference only.
Which databases index PHARMACOTHERAPY?
According to LetPub and DOAJ records, PHARMACOTHERAPY is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed and Embase; that list has not been checked against each database.
Is PHARMACOTHERAPY open access, and what is the APC?
PHARMACOTHERAPY is a hybrid journal. For open-access publication: APC about USD 4,030.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .